Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of some unusual options trading activity on Wednesday. Investors purchased 1,002 put options on the company. This is an increase of approximately 1,791% compared to the average volume of 53 put options.
Maravai LifeSciences Price Performance
Shares of NASDAQ:MRVI opened at $14.01 on Thursday. The firm's 50 day moving average price is $14.12 and its 200-day moving average price is $20.26. Maravai LifeSciences has a twelve month low of $12.16 and a twelve month high of $41.82. The company has a quick ratio of 6.68, a current ratio of 7.22 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $3.58 billion, a PE ratio of 7.83 and a beta of -0.25.
Get
Maravai LifeSciences alerts:
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last released its earnings results on Wednesday, November 2nd. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.05. Maravai LifeSciences had a net margin of 26.29% and a return on equity of 69.19%. The company had revenue of $191.26 million for the quarter, compared to analysts' expectations of $193.83 million. Equities research analysts expect that Maravai LifeSciences will post 1.79 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Maravai LifeSciences from $35.00 to $32.00 and set an "overweight" rating on the stock in a report on Friday, November 4th. UBS Group downgraded shares of Maravai LifeSciences from a "buy" rating to a "neutral" rating and dropped their price target for the company from $20.00 to $16.00 in a report on Thursday, January 5th. Robert W. Baird dropped their price target on shares of Maravai LifeSciences from $34.00 to $25.00 in a report on Thursday, November 3rd. The Goldman Sachs Group dropped their price target on shares of Maravai LifeSciences from $30.00 to $18.00 and set a "buy" rating on the stock in a report on Friday, November 4th. Finally, Royal Bank of Canada assumed coverage on shares of Maravai LifeSciences in a report on Tuesday, December 6th. They set an "outperform" rating and a $22.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Maravai LifeSciences has a consensus rating of "Moderate Buy" and an average target price of $23.22.
Institutional Investors Weigh In On Maravai LifeSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its stake in Maravai LifeSciences by 1.3% during the 1st quarter. Captrust Financial Advisors now owns 33,535 shares of the company's stock worth $1,183,000 after acquiring an additional 442 shares during the period. Xponance Inc. raised its stake in Maravai LifeSciences by 5.3% during the 2nd quarter. Xponance Inc. now owns 12,838 shares of the company's stock worth $365,000 after acquiring an additional 641 shares during the period. Zions Bancorporation N.A. bought a new stake in Maravai LifeSciences during the 1st quarter worth approximately $28,000. ProShare Advisors LLC raised its stake in Maravai LifeSciences by 6.5% during the 3rd quarter. ProShare Advisors LLC now owns 12,804 shares of the company's stock worth $327,000 after acquiring an additional 785 shares during the period. Finally, Signaturefd LLC grew its holdings in Maravai LifeSciences by 200.5% during the 3rd quarter. Signaturefd LLC now owns 1,202 shares of the company's stock valued at $31,000 after buying an additional 802 shares in the last quarter. Institutional investors own 48.67% of the company's stock.
About Maravai LifeSciences
(Get Rating)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
